Timber Pharmaceuticals

Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and other sclerotic skin diseases. The company was founded in 2019 and is headquartered in Basking Ridge, NJ.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2023

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trex Wind-down, Inc. engages in the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibroma in tuberous sclerosis complex, and other sclerotic skin diseases. The company was founded on August 30, 2010 and is headquartered in Warren, NJ.

MADISON, N.J.--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA Timber Pharmaceuticals Inc., a LEO Pharma company, today announced the results for the randomized, double-blind 12-week period of the ASCEND trial. The trial did not show a statistically significant difference between the proportion of patients treated with TMB-001 responding to treatment after 12 weeks compared with patients treated with vehicle. ASCEND is the phase 3 clinical trial of TMB-001, an investigational topica.

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Provides an Update on the Development Program for TMB-001 in Congenital Ichthyosis

MADISON, N.J.--(BUSINESS WIRE)--Timber Pharmaceuticals, Inc., a LEO Pharma Comp., Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis CI.

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma today announced that it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. The TMB-001 project aims to develop a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis – a skin disease with significant unmet need and no approved prescription therapies available. The TMB-001 project continues as planned and w.

LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals

WARREN, N.J., Nov. 29, 2023 — Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to immediately suspend trading in the common stock of Timber Pharmaceuticals, Inc. (the “Company”) — ticker symbol TMBR — from NYSE American. On November 21, 2023, the NYSE American announced that it was commencing proceedings to delist the Company. The Company had the right to request a review of this determination by the Listings Qualifications Pane.

NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)

WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("Timber" or the "Company"), today announced that all "first day" motions related to the Company's voluntary Chapter 11 petitions for reorganization filed on November 17, 2023, were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware.

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Timber Pharmaceuticals, Inc. (the “Company”) — ticker symbol TMBR — from NYSE American. NYSE Regulation has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Section 1003(c)(iii) of the NYSE American Company Guide in light of the Compa.

NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR)

WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the “NYSE American”) has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.

Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Timber Pharmaceuticals, Inc. (“the Company”) (NYSE: TMBR) to LEO Pharma A/S. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company's shareholders. If you would like to discuss your legal rights regarding the proposed sale, you may, without oblig.

TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR

Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.

Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Timber Pharmaceuticals, Inc. (NYSE: TMBR) to LEO Pharma A/S is fair to Timber shareholders. Halper Sadeh encourages Timber shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Timber and its board of directors viola.

TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders

Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is undergoing a massive rally on Monday after announcing that Leo US is acquiring it in a $36 million deal. According to a press release from Timber Pharmaceuticals, that acquisition has an upfront payment of $14 million for TMBR stock.

Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals.

LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals

WARREN, NJ, Aug. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR) today announced that it has entered into a definitive agreement to be acquired by LEO US Holding, Inc. (“LEO Pharma”), a wholly-owned subsidiary of LEO Pharma A/S, in a total transaction value of up to $36 million with (i) an initial upfront consideration of $14 million and (ii) up to an additional $22.0 million in contingent value rights (CVRs) payable upon achievement of certain milestones described below. All of the issued and outstanding shares of capital stock and other equity interests of Timber will be converted into the right to receive the initial upfront consideration, less the payments for certain outstanding warrants that contain a Black Scholes cash payout value. For example, based on a current estimate of the Black Scholes value of such warrants of approximately $5.1 million, subject to change based on the assumptions detailed below, Timber expects the initial amount per share to be paid to Timber stockholders to be approximately $2.62 based on approximately 3.4 million shares of Timber common stock and restricted stock issued and outstanding as of August 20, 2023.

Timber Pharmaceuticals to be Acquired by LEO Pharma

WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 28, 2023 it received a letter (the “Notice”) from the NYSE American LLC (“NYSE American” or the “Exchange”) advising the Company is not in compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide given the reported stockholders' deficit as of March 31, 2023, and losses from continuing operations and/or net losses in its four most recent fiscal years then ended.

Timber Pharmaceuticals Discloses Communication From NYSE American

- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin -

Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

Timber (TMBR) receives a dermal carcinogenicity waiver from the FDA for TMB-001, which is being developed to treat moderate-to-severe subtypes of congenital ichthyosis.

Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001

- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled -

Timber Pharmaceuticals Announces FDA Grant of CARC Waiver for TMB-001

- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. John Koconis, Chairman and Chief Executive Officer of Timber, commented, “The development of our lead asset, TMB-001, continued to progress on several fronts during the first quarter of 2023.

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

Timber Pharmaceuticals, Inc. (TMBR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now

- Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI -

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis -

Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL study in Clinical and Experimental Dermatology

Cingulate

Troika Media Group

Use these tips for buying penny stocks for the long term The post Building a Penny Stocks Portfolio For Long Term  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Building a Penny Stocks Portfolio For Long Term

Bed Bath & Beyond

Use these tips to analyze penny stocks The post Penny Stock Investing: How to Analyze Market Conditions appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stock Investing: How to Analyze Market Conditions

Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is taking off on Friday after getting an orphan drug designation in Europe. That comes from the EC and covers TMB-001 for the treatment of X-linked recessive ichthyosis.

News for Timber Pharmaceuticals Stock (TMBR)